News


All News


June 12, 2026

Woven Solutions Acquires Insignis to Expand Cyber Capabilities

Woven Solutions has acquired Insignis to strengthen its capabilities in cybersecurity, systems engineering, software development, and mission-focused technology services. The acquisition enhances Woven’s ability to support national security operations while expanding its presence in the U.S. government technology sector. [...]


June 11, 2026

Harbinger Introduces Next-Gen Unmanned Military Platform

Harbinger has introduced a new hybrid-electric unmanned ground vehicle platform designed for modern military operations. Developed through its defense division, Praesidia, the vehicle supports logistics, troop transport, communications, anti-drone missions, and security operations. Featuring hybrid-electric propulsion, teleoperated controls, onboard power generation, and dual communication systems [...]


June 10, 2026

Thoma Bravo Deepens Software Buyout Strategy with Kneat Acquisition

Thoma Bravo has acquired Kneat in an all-cash transaction valued at C$650 million, highlighting growing demand for compliance and validation software in regulated industries. The deal strengthens Thoma Bravo’s presence in life sciences technology while supporting innovation in digital validation, quality management, and regulatory compliance solutions. Increased adoption of automated compliance pl [...]


June 09, 2026

Accenture Acquires Whalar to expand influence in fast-growing creator economy

Accenture has acquired Whalar to strengthen its creator marketing capabilities through Accenture Song. The deal combines Whalar’s global creator network and influencer marketing expertise with Accenture’s AI-driven marketing technologies, enabling brands to enhance customer engagement, social commerce, and digital marketing performance worldwide. [...]


June 08, 2026

Regeneron Advances Disease Research Across Key Pipelines

Regeneron Pharmaceuticals will present new findings at ADA 2026 and ENDO 2026, highlighting advances in obesity treatment, muscle preservation, ophthalmology, and rare disease therapies. The data reinforce its commitment to addressing unmet medical needs through innovative research. [...]


June 08, 2026

Google and SpaceX Sign Multi-Year AI Compute Agreement

Google has entered a multi-year cloud computing agreement with SpaceX to secure access to large-scale AI infrastructure, including approximately 110,000 Nvidia GPUs. The partnership reflects growing demand for high-performance computing resources required for AI model training and deployment. The deal is expected to strengthen AI infrastructure capabilities, support enterprise cloud services, and [...]


June 04, 2026

Stryker Unveils TPX HD Tool for Orthopedic Surgery

Stryker has expanded its orthopedic technology portfolio with the launch of the TPX HD power tool. Designed for complex orthopedic, revision, and maxillofacial procedures, the system delivers up to 296% more torque and 40% greater speed than previous models. Featuring improved ergonomics, enhanced visibility, customizable controls, and specialized attachments, TPX HD aims to improve surgical preci [...]


June 03, 2026

Encina and BASF Deepen Alliance for Circular Chemicals

BASF and Encina Development Group have expanded their strategic partnership to accelerate the growth of circular chemicals globally. The collaboration supports Encina’s Gulf Coast manufacturing project, advances chemical recycling technologies, and strengthens sustainable feedstock supply chains. By converting end-of-life plastics into valuable chemical raw materials, both companies aim to support [...]


June 02, 2026

FluidCrystal Expansion Strengthens Lilly-Camurus Alliance

Camurus has expanded its collaboration with Eli Lilly, adding amylin receptor agonists to its FluidCrystal-based long-acting drug delivery program, strengthening development in obesity and diabetes treatments. [...]


June 01, 2026

FDA Approves Durvalumab for High-Risk Bladder Cancer

The FDA has approved durvalumab (Imfinzi®) in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). Supported by Phase 3 POTOMAC trial data, the approval demonstrated improved disease-free survival compared with BCG alone, marking a significant advancement in bladder cancer treatment and expanding the role of immunotherapy in earlier-stage disease ma [...]